Arrowhead Pharmaceuticals (ARWR) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.36
- EPS estimate
- −$1.28
- EPS surprise
- −6.52%
- Revenue surprise
- +70.36%
- Revenue
- $75.3M
- Revenue estimate
- $44.2M
- Reported
- Aug 4, 2026
Arrowhead Pharmaceuticals reported fiscal Q3 2026 results on August 4, 2026. It posted a loss of $1.36 per share, wider than the $1.28 loss expected, a 6.52% miss. Revenue of $75.3 million was well above the $44.2 million estimate, a 70.36% beat. A year earlier, in fiscal Q3 2025, the loss was $1.26 per share on $27.8 million of revenue.
Arrowhead lost money in 16 of the last 20 quarters. The profitable ones were fiscal Q2 2022, Q2 2023, Q2 2025 and Q1 2026. Fiscal Q2 2025 stands out, with $542.7 million of revenue and EPS of $2.75, both highs here. Annual losses per share were $1.67 in fiscal 2022, $1.92 in 2023 and $5.00 in 2024. Fiscal 2025 came close to break-even at a loss of $0.01. The first three quarters of fiscal 2026 add up to a loss of $2.07. EPS missed the estimate in 14 of the 20 quarters, and the table shows no revenue for three quarters of fiscal 2024.
Arrowhead reported fiscal Q4 between November 22 and November 29 in each of the past five years. That points to late November 2026 for the next report, which will complete fiscal 2026.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Aug 4, 2026 | −$1.28 | −$1.36 | −6.52% | $75.3M | SEC |
| Q2 2026 | May 7, 2026 | −$1.10 | −$0.93 | +15.07% | $73.7M | SEC |
| Q1 2026 | Feb 5, 2026 | $0.04 | $0.22 | +491.40% | $264.0M | SEC |
| Q4 2025 | Nov 25, 2025 | −$0.11 | −$0.11 | +1.43% | $256.5M | SEC |
| Q3 2025 | Aug 7, 2025 | −$0.95 | −$1.26 | −32.31% | $27.8M | SEC |
| Q2 2025 | May 12, 2025 | −$0.19 | $2.75 | +1567.45% | $542.7M | SEC |
| Q1 2025 | Feb 10, 2025 | −$0.48 | −$1.39 | −192.08% | $2.5M | SEC |
| Q4 2024 | Nov 26, 2024 | −$1.12 | −$1.36 | −21.39% | $0.00 | SEC |
| Q3 2024 | Aug 8, 2024 | −$0.53 | −$1.38 | −160.92% | $0.00 | SEC |
| Q2 2024 | May 9, 2024 | −$0.47 | −$1.02 | −116.15% | $0.00 | SEC |
| Q1 2024 | Feb 6, 2024 | −$0.80 | −$1.24 | −54.81% | $3.6M | SEC |
| Q4 2023 | Nov 29, 2023 | −$0.61 | −$1.02 | −67.60% | $16.1M | SEC |
| Q3 2023 | Aug 7, 2023 | −$0.57 | −$0.96 | −68.63% | $15.8M | SEC |
| Q2 2023 | May 2, 2023 | −$0.62 | $0.45 | +172.82% | $146.3M | SEC |
| Q1 2023 | Feb 6, 2023 | $0.37 | −$0.39 | −205.43% | $62.5M | SEC |
| Q4 2022 | Nov 28, 2022 | −$0.58 | −$0.80 | −36.99% | $31.6M | SEC |
| Q3 2022 | Aug 4, 2022 | −$0.57 | −$0.68 | −19.59% | $32.4M | SEC |
| Q2 2022 | May 10, 2022 | $0.14 | $0.41 | +182.95% | $151.8M | SEC |
| Q1 2022 | Feb 2, 2022 | −$0.45 | −$0.60 | −34.26% | $27.4M | SEC |
| Q4 2021 | Nov 22, 2021 | $0.05 | −$0.61 | −1376.15% | $38.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Arrowhead Pharmaceuticals (ARWR) last report earnings?
Arrowhead Pharmaceuticals last reported on Aug 4, 2026, covering fiscal Q3 2026.
Did ARWR beat earnings estimates?
No. Arrowhead Pharmaceuticals reported EPS of −$1.36 for Q3 2026 against a −$1.28 estimate — a 6.52% miss.
How much revenue did ARWR report last quarter?
Arrowhead Pharmaceuticals reported $75.3M in revenue for Q3 2026, against a consensus estimate of $44.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.